DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Atorvastatin for the Treatment of Retinal Vein Occlusion

Information source: University of Toronto
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Retinal Vein Occlusion; Retinal Vein Thrombosis; Central Retinal Vein Occlusion; Branch Retinal Vein Occlusion; Thrombosis

Intervention: Atorvastatin (Drug); Placebo (Drug)

Phase: Phase 3

Status: Recruiting

Sponsored by: University of Toronto

Official(s) and/or principal investigator(s):
Joel G Ray, MD MSc, Principal Investigator, Affiliation: St. Michael's Hospital, University of Toronto
David Wong, MD, Principal Investigator, Affiliation: St. Michael's Hospital, University of Toronto

Overall contact:
Brigita Zile Zile, RN, Phone: 416-864-6060, Ext: 4130, Email: zileb@smh.toronto.on.ca

Summary

The ATORVO study is designed to determine whether atorvastatin (Lipitor) can improve vision, when compared to placebo

Clinical Details

Official title: Atorvastatin Toronto Retinal Vein Occlusion Study (ATORVO)

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Difference in improvement of at least 15 letters (3 lines) in Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity in the affected eye at 24 weeks in patients on active treatment vs. placebo.

Secondary outcome:

Prevention of ocular neovascularization or need for laser treatment by 24 weeks.

Reduction in macular edema, measured by optical coherence tomography at 24 weeks.

Mean change in The National Eye Institute 25-Item Visual Function Questionnaire-25 (VFQ-25) score from 0 to 24 weeks.

Composite of non-fatal myocardial infarction, hospitalization for acute coronary syndrome, receipt of coronary revascularization, stroke or death, by 52 weeks.

Mean change in the concentration of serum total cholesterol, LDL-cholesterol and highly sensitive C-reactive protein at 0 and 24 weeks.

Detailed description: Retinal vein occlusion (RVO), a common cause of visual loss in the Western world, is a disease whose etiology resembles that of classic atherosclerosis. A therapy that lowers the risk of arterial and venous thrombosis would seem to be a reasonable approach to managing this disease, for which there is currently no treatment. ATORVO is a randomized double-masked clinical trial comparing a daily dose of 80 mg of atorvastatin to matched placebo in persons recently diagnosed with RVO. At 24 weeks after randomization, we will evaluate each participant's visual acuity and the presence of secondary complications related to RVO.

Eligibility

Minimum age: 40 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Adults aged 40 years and older

- Diagnosed with CRVO or BRVO

- Visual acuity of 20/40 or worse in the affected eye

- Onset of current symptoms of loss of vision within the past 60 days

- Ability to understand spoken English

Exclusion Criteria:

- Current use of a statin or fibrate medication

- Known cardiovascular disease or revascularization, including coronary artery disease

(myocardial infarction or angina), stroke or peripheral artery occlusion

- Known diabetes mellitus

- Known liver disease

- Serum low-density lipoprotein cholesterol (LDL-C) > 5. 0 mmol/L

- Baseline serum triglycerides > 6. 0 mmol/L

- Serum ALT above 115 U/L (i. e., 2. 5 x upper limit of normal)

- Baseline serum creatinine > 250 µmol/L

- Ocular surgery within the past 90 days

- Planned ocular or cataract surgery within the study period

- Known retinal disease: age-related macular degeneration, retinal detachment or

macular hole, or past history of vein occlusion

- Women who are pregnant or who are breastfeeding

- Participation in another clinical trial concurrently or within 30 days prior to

screening

- Known allergy to fluorescein dye

- Current use of cyclosporine medication.

- Current use of an HIV protease inhibitor medication.

Locations and Contacts

Brigita Zile Zile, RN, Phone: 416-864-6060, Ext: 4130, Email: zileb@smh.toronto.on.ca

St. Michael's Hospital, Toronto, Ontario M5B 1W8, Canada; Recruiting
Brigita Zile, RN CCRP, Phone: 416-864-6060, Ext: 4130, Email: zileb@smh.toronto.on.ca
Joel G Ray, MD MSc, Principal Investigator
David T Wong, MD, Principal Investigator
Larry Leiter, MD, Sub-Investigator
Shaun Goodman, MD MSc, Sub-Investigator
Anatoly Langer, MD, Sub-Investigator
Additional Information

Starting date: August 2007
Last updated: June 23, 2008

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017